







an Open Access Journal by MDPI

p53 Signaling in Cancers

Guest Editor:

Dr. Natalia Issaeva

Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Deadline for manuscript submissions:

closed (15 April 2018)

Message from the Guest Editor

Dear Colleagues,

This Special Issue is about the unique tumor suppressor p53. The exclusivity of this gene begins from its discovery it was originally believed to be an oncogene, but genetic and functional data obtained ten years after its discovery showed it to be a powerful natural tumor suppressor. The most commonly-mutated gene in cancer, a major responder to stress conditions, and a potent regulator of transcription and a strong player in signaling to apoptosis, p53 became one of the most attractive molecular targets in cancer therapy; together with p53 animal models, p53 reactivating molecules, in turn, appeared to be a great tool to study p53 cellular functions. Recently-discovered p53 activities in metabolism, immunity, epigenetic regulation and non-apoptotic cell death evidently showed that we are still far away from a clear understanding of how p53 exerts its tumors suppressor functions. Here, we welcome papers outlining mechanisms of p53 control and p53 roles in cancer and normal tissues.

Dr. Issaeva Natalia Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us